Direct Marketing in the next 40 years...

Share this article:
As the mass marketing approach has become considered increasingly less effective, CRM and direct-to-patient initiatives are being thrust to the forefront of pharma marketers' efforts.

“There is an overall decline in effectiveness of DTC in light of a plethora of alternative media channels,” says Wunderman COO Becky Chidester. “This is forcing marketers to rethink channel strategies. Relationship marketing, including the Web and new digital channels, is the beneficiary of this change.”

Harte-Hanks' SVP, pharmaceutical markets, Julian Parreño adds, “All of these things make media planning more challenging than ever.”

According to Parreño, the direct marketing medium will continue to grow in prominence due to the database technology available and the importance of customer loyalty and lifetime value to the bottom line.

New technology has tremendous implications for the patient/physician relationship that direct marketers hope to achieve, says Lynn Benzing, president of Patient Marketing Group.  “Consumers are now able to access a vast array of condition-specific information on the Web, leading to increasing patient sophistication. This, coupled with DTC advertising, has led to a scenario where patients are more likely to ask complex questions, and request specific treatment options.”

Consumers are now more savvy and demanding as healthcare customers. 

Benzing says, “The power of the Internet to serve up personalized and relevant information at a fraction of the cost of other communication media has revolutionized the ability of pharmaceutical manufacturers to offer highly interactive health education information online, which leads to being a successful marketer in the future.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.